Edgewise Therapeutics, Inc. Balance Sheet
EWTX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Edgewise Therapeutics, Inc. had $553M in total assets and $522M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M | $104.9M |
| Current Assets | $543.4M | $475.5M | $327.0M | $357.0M | $283.8M | $129.6M |
| PP&E (Net) | $7.8M | $9.5M | $10.4M | $8.5M | $912.0K | $516.0K |
| Total Assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M | $131.1M |
| Current Liabilities | $27.4M | $23.9M | $16.8M | $16.6M | $10.5M | $4.3M |
| Shareholders' Equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M | -$33.4M |